VX-765: Potent and Selective Caspase-1 Inhibitor for Precision Inflammation Research

Executive Summary: VX-765 is a highly selective and orally bioavailable caspase-1 inhibitor that suppresses IL-1β and IL-18 release during inflammasome activation (Exconde et al., 2023). It is rapidly metabolized in vivo to its active form, VRT-043198, ensuring potent inhibition of caspase-1 enzymatic activity. VX-765 demonstrates robust anti-inflammatory efficacy in cell and mouse models of rheumatoid arthritis and skin inflammation [APExBIO]. The compound does not alter secretion of unrelated cytokines, supporting its utility for dissecting caspase-1-dependent pathways. Its high solubility in DMSO and ethanol, but not water, and stringent storage guidelines enable reliable integration into biochemical and preclinical workflows.

Biological Rationale

The mammalian innate immune system relies on pattern-recognition receptors (PRRs) to detect pathogen-associated and damage-associated molecular patterns. These PRRs assemble into inflammasomes, which activate caspase-1 (also known as interleukin-1 converting enzyme, ICE) (Exconde et al., 2023). Active caspase-1 processes pro-IL-1β and pro-IL-18 into their mature, secreted forms, acting as central mediators of inflammation. Caspase-1 also cleaves gasdermin D, initiating pyroptosis, a lytic form of programmed cell death in macrophages. Dysregulated caspase-1 activity is implicated in chronic inflammatory diseases, including rheumatoid arthritis and HIV-associated immune activation. Selective inhibition of caspase-1 is a validated strategy to attenuate these inflammatory responses without broadly suppressing immune function [VX-765: Advancing the Frontier...]; this article extends those insights by providing a detailed, evidence-based parameter map for VX-765 integration.

Mechanism of Action of VX-765, Caspase-1 inhibitor, potent and selective

VX-765 is a pro-drug that undergoes in vivo conversion to VRT-043198, the direct inhibitor of caspase-1 enzymatic activity [APExBIO]. VRT-043198 binds to the active site of caspase-1, preventing cleavage of pro-inflammatory substrates such as pro-IL-1β and pro-IL-18. This blockade inhibits maturation and secretion of these cytokines, curtailing downstream inflammatory signaling. VX-765 does not inhibit other caspases or cytokine secretion (e.g., IL-6, TNFα, IL-8), confirming its selectivity for the ICE/caspase-1 subfamily. Canonical inflammasome activation, via PRR and ASC recruitment, leads to caspase-1 auto-proteolysis and full activity; VX-765 interrupts this pathway at the enzymatic step, halting both cytokine release and pyroptosis (Exconde et al., 2023). Non-canonical inflammasome pathways, involving caspase-4/5/11, are not directly targeted by VX-765.

Evidence & Benchmarks

• VX-765 is metabolized to VRT-043198, which inhibits caspase-1 with high potency in cell-based assays (IC₅₀ values in the low nanomolar range) (APExBIO).
• In macrophage models, VX-765 suppresses LPS-induced release of IL-1β and IL-18, but not IL-6, TNFα, or IL-8 (Exconde et al., 2023).
• Oral VX-765 administration (50–100 mg/kg, daily, p.o.) reduces inflammation markers and cytokine levels in mouse models of rheumatoid arthritis and skin inflammation (APExBIO).
• VX-765 prevents CD4 T-cell pyroptotic death in ex vivo HIV-infected human lymphoid tissue in a dose-dependent manner (Immuneland).
• VX-765 does not block non-canonical inflammasome (caspase-4/5/11) activation or the direct cleavage of IL-18 by these proteases (Exconde et al., 2023).

This article clarifies and updates the mechanistic focus presented in "Strategic Caspase-1 Targeting: VX-765 as a Next-Generation Tool" by providing direct, evidence-based selectivity and workflow parameters.

Applications, Limits & Misconceptions

VX-765 is widely used in inflammation, pyroptosis, and cytokine signaling research. It is suitable for:

• Dissecting caspase-1-dependent cytokine maturation in cell and animal models.
• Evaluating anti-inflammatory efficacy in chronic disease models, e.g., rheumatoid arthritis and skin inflammation.
• Studying the inhibition of pyroptosis in macrophages and HIV-infected lymphoid tissues.
• Biochemical caspase assays using ICE-specific substrates (e.g., suc-YVAD-pNA).

Common Pitfalls or Misconceptions

• VX-765 does not inhibit non-canonical inflammasome caspases (caspase-4, -5, -11) or their cytokine processing activities (Exconde et al., 2023).
• It does not block the secretion of cytokines unrelated to caspase-1, such as IL-6, TNFα, or IL-8.
• VX-765 is not soluble in water; use DMSO (≥313 mg/mL) or ethanol (≥50.5 mg/mL with ultrasonication) for stock solutions (APExBIO).
• It is not suitable for direct in vitro use without metabolic activation (conversion to VRT-043198).
• Improper storage (> -20°C or exposure to moisture) reduces compound stability.

Compared to "Selective Caspase-1 Inhibition with VX-765: Charting a New Roadmap", this article prioritizes practical pitfalls and integration details for reproducible experimental success.

Workflow Integration & Parameters

VX-765 (A8238) from APExBIO is supplied as a solid, requiring desiccated storage at -20°C. Prepare stock solutions in DMSO or ethanol as indicated; avoid water. Solutions are recommended for short-term use (<7 days at -20°C, protected from light and moisture). For in vivo studies, oral dosing (50–100 mg/kg) has demonstrated efficacy in mouse models. For in vitro work, ensure metabolic conversion or use the active metabolite (VRT-043198) if direct enzymatic inhibition is required. Analytical readouts should include caspase-1 activity assays (YVAD-pNA substrate, absorbance at 405 nm), cytokine ELISA (IL-1β, IL-18), and assessment of pyroptosis (lactate dehydrogenase release or gasdermin D cleavage).

For strategic guidance on advanced model selection and translational outcomes with VX-765, see "VX-765: Selective Caspase-1 Inhibitor for Pyroptosis and Inflammation", which this article extends by specifying precise workflow integration and storage/solubility parameters.

Conclusion & Outlook

VX-765 stands as a robust, selective, and practical tool for caspase-1-dependent inflammation and pyroptosis research. Its validated selectivity for the ICE/caspase-1 subfamily enables targeted modulation of IL-1β and IL-18, with no off-target cytokine suppression. APExBIO's VX-765 (A8238) is benchmarked for high purity, stability, and translational compatibility. As mechanistic insights into inflammasome biology advance, VX-765 will remain integral for dissecting canonical pathways and guiding therapeutic innovation. For additional product details, visit the VX-765, Caspase-1 inhibitor, potent and selective product page.